Inactive Instrument

IMARA

Equities

IMRA

US45249V1070

IMARA INC. Financial Statements and Exhibits (form 8-K/A)

November 16, 2022 at 06:04 am EST

Item 9.01 Financial Statements and Exhibits.

(b) The unaudited pro forma condensed consolidated financial information of the Company as of and for the nine months ended September 30, 2022, and the unaudited pro forma condensed consolidated financial information of the Company for the fiscal year ended December 31, 2021 as required by Item 9.01(b) are attached as Exhibit 99.1 to this Current Report on Form 8-K/A and incorporated herein by reference.



(d) Exhibits

Exhibit
  No.       Description

99.1          Unaudited Pro Forma Condensed Consolidated Financial Information.

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

Latest news about IMARA

Enliven Therapeutics Completes Merger With Imara	23-02-24	MT
IMARA Inc.(NasdaqGS:IMRA) dropped from NASDAQ Composite Index	23-02-23	CI
Enliven Therapeutics, Inc. completed the acquisition of IMARA Inc. from a group of shareholders for approximately $340 million in a reverse merger transaction.	23-02-22	CI
IMARA Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-10	CI
Top Premarket Decliners	23-01-09	MT
Cardurion Pharmaceuticals, LLC acquired Tovinontrine (IMR-687) and All of the Assets Related to PDE9 Program from IMARA Inc. for approximately $95.	22-11-09	CI
IMARA Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-25	CI
Sector Update: Health Care Stocks Ending with Modest Declines	22-10-14	MT
Sector Update: Health Care Stocks Sliding with Broader Friday Markets	22-10-14	MT
Top Midday Gainers	22-10-14	MT
Wall Street Set to Open Higher as Earnings Season Accelerates, Ahead of Consumer Sentiment Survey	22-10-14	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	22-10-14	MT
Sector Update: Health Care	22-10-14	MT
US Stock Futures Mixed as Earnings Season Accelerates, Ahead of Consumer Sentiment Survey	22-10-14	MT
Top Premarket Gainers	22-10-14	MT
Arix Bioscience Portfolio Company Imara To Merge With Enliven Therapeutics	22-10-14	MT
IMARA, Enliven Therapeutics to Merge in All-Stock Deal; Shares Rise After Hours	22-10-13	MT
Transcript : Enliven Therapeutics, Inc., IMARA Inc. - M&A Call	22-10-13
Enliven Therapeutics, Inc. entered into a definitive merger agreement to acquire IMARA Inc. from a group of shareholders in a reverse merger transaction.	22-10-12	CI
Sector Update: Health Care Stocks Gaining Steam in Late Trade	22-09-07	MT
Sector Update: Health Care Stocks Rebounding Wednesday After Long Retreat	22-09-07	MT
Top Midday Gainers	22-09-07	MT
Sector Update: Health Care	22-09-07	MT
Imara to Sell Tovinontrine, PDE9 Program-Related Assets to Cardurion Pharmaceuticals; Shares Rise	22-09-07	MT
Top Premarket Gainers	22-09-07	MT

Chart IMARA

Duration

Period

More charts

Company Profile

Imara, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9). PDE9 selectively degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule. IMR-687 is in Phase IIb clinical development for the treatment of sickle cell disease (SCD) and beta- thalassemia. It is also focused on initiating a Phase II clinical trial of IMR-687 in heart failure with preserved ejection fraction (HFpEF). The Company is also focused on development of IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2-related factor 2 (Nrf2).

Sector

More about the company